Summary:
This is a Phase 2, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging, multicenter study to evaluate the safety and efficacy of lutikizumab in adult subjects with moderate to severe HS who have failed anti-TNF therapy.
The study is comprised of a 35-day Screening Period, a 16-week double-blind placebo-controlled Treatment Period, and a 9-week Follow-Up Period (10 weeks after the last dose of study drug).
Qualified Participants Must:
• Have a diagnosis of Hidradenitis Suppurativa
• Have Failed Anti-TNF Therapy (Humira, Cimzia, or Enbrel)
Qualified Participants May Receive:
All Study related procedures and office visits with a board certified dermatologist at no charge.